当前位置：
X-MOL 学术
›
Cancer Cell
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy
Cancer Cell ( IF 48.8 ) Pub Date : 2024-08-29 , DOI: 10.1016/j.ccell.2024.08.004 Christopher A Eide 1 , Diana Brewer 1 , Tao Xie 2 , Anna Reister Schultz 1 , Samantha L Savage 1 , Serena Muratcioglu 3 , Noah Merz 1 , Richard D Press 4 , Thomas O'Hare 5 , Thomas Jacob 6 , Tania Q Vu 7 , Cristina E Tognon 1 , Tara A Macey 1 , John Kuriyan 8 , Charalampos G Kalodimos 2 , Brian J Druker 1
Cancer Cell ( IF 48.8 ) Pub Date : 2024-08-29 , DOI: 10.1016/j.ccell.2024.08.004 Christopher A Eide 1 , Diana Brewer 1 , Tao Xie 2 , Anna Reister Schultz 1 , Samantha L Savage 1 , Serena Muratcioglu 3 , Noah Merz 1 , Richard D Press 4 , Thomas O'Hare 5 , Thomas Jacob 6 , Tania Q Vu 7 , Cristina E Tognon 1 , Tara A Macey 1 , John Kuriyan 8 , Charalampos G Kalodimos 2 , Brian J Druker 1
Affiliation
No Abstract
中文翻译：
用 ponatinib 和 asciminib 联合治疗克服临床 BCR-ABL1 化合物突变耐药
无摘要
更新日期：2024-08-29
中文翻译：
用 ponatinib 和 asciminib 联合治疗克服临床 BCR-ABL1 化合物突变耐药
无摘要
京公网安备 11010802027423号